Biosino Bio-Technology and Science (HKSE:08247) Debt-to-Equity : 0.72 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Biosino Bio-Technology and Science Debt-to-Equity?

Biosino Bio-Technology and Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$159.7 Mil. Biosino Bio-Technology and Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$6.0 Mil. Biosino Bio-Technology and Science's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$230.1 Mil. Biosino Bio-Technology and Science's debt to equity for the quarter that ended in Dec. 2023 was 0.72.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biosino Bio-Technology and Science's Debt-to-Equity or its related term are showing as below:

HKSE:08247' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.72 Max: 1.16
Current: 0.72

During the past 13 years, the highest Debt-to-Equity Ratio of Biosino Bio-Technology and Science was 1.16. The lowest was 0.00. And the median was 0.72.

HKSE:08247's Debt-to-Equity is ranked worse than
77.72% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs HKSE:08247: 0.72

Biosino Bio-Technology and Science Debt-to-Equity Historical Data

The historical data trend for Biosino Bio-Technology and Science's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosino Bio-Technology and Science Debt-to-Equity Chart

Biosino Bio-Technology and Science Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.98

1.16

0.99

0.74

0.72

Biosino Bio-Technology and Science Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.74	N/A	0.78	N/A	0.72

Competitive Comparison of Biosino Bio-Technology and Science's Debt-to-Equity

For the Diagnostics & Research subindustry, Biosino Bio-Technology and Science's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biosino Bio-Technology and Science's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biosino Bio-Technology and Science's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biosino Bio-Technology and Science's Debt-to-Equity falls into.

Biosino Bio-Technology and Science Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biosino Bio-Technology and Science's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(159.668	+	5.985)	/	230.117
	=	0.72

Biosino Bio-Technology and Science's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(159.668	+	5.985)	/	230.117
	=	0.72

Biosino Bio-Technology and Science (HKSE:08247) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biosino Bio-Technology and Science Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biosino Bio-Technology and Science's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosino Bio-Technology and Science (HKSE:08247) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biosino Bio-Technology and Science Inc (HKSE:08247) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, CHN, 102200

Website

http://www.zhongsheng.com.cn

Biosino Bio-Technology and Science Inc is engaged in the manufacture, sale, and distribution of in-vitro diagnostic (IVD) reagent products. the company's revenue is generated from customers located in Mainland China.

Executives

Beijing Enterprises Group Company Limited	2201 Interest of corporation controlled by you
Beijing Enterprises Holdings Limited	2101 Beneficial owner
Hk Zhixin Investment Co., Ltd.	2101 Beneficial owner
Li Dongfeng	2201 Interest of corporation controlled by you
Yan Kang	2201 Interest of corporation controlled by you
Qiu Zhe Feng	2201 Interest of corporation controlled by you
Hai Nan Zhi Xin Tou Zi He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Yun Nan Sheng Neng Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Li Yang Yi Xiong	2201 Interest of corporation controlled by you

Biosino Bio-Technology and Science (HKSE:08247) Headlines

No Headlines